U.S. Artificial Retina Market Size, Share & Forecast 2026–2032
Report Highlights
- ✓Country: United States
- ✓Market: Artificial Retina
- ✓Market Size 2024: USD 38.5 million
- ✓Market Size 2032: USD 112.0 million
- ✓CAGR: 14.3%
- ✓Base Year: 2025
- ✓Forecast Period: 2026–2032
Analyst Recommendation — Secure Academic Trial Partnerships: Device developers and hospital investors should secure an IDE-approved trial partnership with a leading academic eye center by Q4 2026. Early U.S. enrollment strengthens TCET coverage eligibility, and late entrants will lose years of market access.
Artificial Retinas in the United States: Market Overview
The U.S. artificial retina market is a clinical-stage niche within ophthalmic devices, valued at an estimated USD 38.5 million in 2024 and forecast to reach USD 112.0 million by 2032. Unlike the global market, where demand spreads across broader retinal disease categories and multiple geographies, U.S. activity centers on retinitis pigmentosa and other inherited retinal dystrophies affecting roughly 100,000 Americans. Revenue arrives through individual implant procedures and trial milestones rather than recurring consumables.
Argus II, developed by Second Sight Medical Products, received Humanitarian Device Exemption authorization from the FDA in 2013 and remains the only retinal prosthesis that has reached U.S. patients commercially. Second Sight's 2022 withdrawal from commercial support left the category without an active domestic sponsor, forcing the market to rebuild around subretinal and suprachoroidal designs. Consequently, the market structure is defined by pipeline assets and academic trial sites rather than established supplier revenue.
Growth Drivers Behind Artificial Retinas in the United States
Three demand drivers are shaping the U.S. market. First, the National Eye Institute, operating on an annual budget of roughly USD 900 million, funds sustained inherited retinal disease research at centers including the Wilmer Eye Institute at Johns Hopkins and the Cole Eye Institute at Cleveland Clinic. Second, retinitis pigmentosa prevalence near 1 in 4,000 Americans creates a durable eligible pool, while advanced dry age-related macular degeneration affecting over one million Americans offers a longer-term expansion pathway.
Third, regulatory acceleration is lowering the cost of reaching market. FDA's Breakthrough Devices Program, codified under the 21st Century Cures Act of 2016, gives sponsors priority interaction with CDRH reviewers. CMS's Transitional Coverage for Emerging Technologies pathway, finalized in 2024, provides a route to Medicare coverage for designated breakthrough devices while evidence matures, shortening the gap between pivotal data and paid utilization.
Market Restraints and Entry Barriers
Regulatory structure is the dominant barrier. Most new retinal prostheses must complete a pivotal study under an Investigational Device Exemption governed by 21 CFR Part 812 and secure premarket approval under 21 CFR Part 814. The Humanitarian Device Exemption pathway offers a shortcut but caps annual distribution at 8,000 devices and cannot support broad commercial revenue, limiting its value for a full national launch.
Clinical infrastructure and reimbursement form the second barrier. Implantation requires specialized vitreoretinal surgeons working at a limited network of qualified U.S. centers, and patient selection depends on residual retinal architecture that many candidates lack. Entrants must also align with the Quality Management System Regulation, effective February 2, 2026, which aligns 21 CFR Part 820 with ISO 13485, and secure Medicare Part B coding before hospitals commit operating room time.
Market Opportunities for Artificial Retinas in the United States
The most immediate opportunity is a subretinal platform entering U.S. pivotal evaluation. Science Corporation's PRIMA system has a plausible U.S. addressable base of roughly 15,000 to 20,000 Americans with severe retinitis pigmentosa who retain light perception, according to analyst estimates derived from NEI prevalence data. Securing Breakthrough designation and early IDE sites in the Northeast and Midwest would position a launch around 2028.
A second opportunity lies in service and reactivation. Argus II recipients still require device maintenance, and U.S. patients whose systems lost support need explant, replacement, or upgrade pathways. Veterans Affairs medical centers, which procure specialty ophthalmic equipment through national contracting, represent a further channel with predictable procurement cycles and a veteran population affected by inherited and trauma-related retinal disease.
Market at a Glance
| Metric | Value |
|---|---|
| Market Size 2024 | USD 38.5 million |
| Market Size 2032 | USD 112.0 million |
| Growth Rate (CAGR) | 14.3% |
| Most Critical Decision Factor | FDA marketing pathway and Medicare reimbursement coverage |
| Largest Region | Northeast and Midwest academic eye centers |
| Competitive Structure | Fragmented, pre-commercial, with few FDA-authorized devices |
Leading Market Participants
- Second Sight Medical Products
- Science Corporation
- Pixium Vision
- Retina Implant AG
- Nanoretina
- Bionic Vision Technologies
- Optobionics
- Wilmer Eye Institute
- Doheny Eye Institute
- Cole Eye Institute
Regulatory and Policy Environment
FDA's Center for Devices and Radiological Health supervises retinal prosthesis filings under the Federal Food, Drug, and Cosmetic Act. Investigational studies follow 21 CFR Part 812, with IDE decisions due within 30 days, while Humanitarian Device Exemption requests fall under 21 CFR Part 814 Subpart H with a 75-day review target. Premarket approval reviews run on a nominal 180-day clock but typically extend to 12 months or more once major deficiencies are resolved.
Reimbursement and funding policy complete the framework. CMS administers Medicare Part B coverage, and its Transitional Coverage for Emerging Technologies pathway, finalized in 2024, allows up to five designated breakthrough devices per year to receive provisional coverage with evidence development. MDUFA V user fees fund FDA review staffing through fiscal 2027, while NEI's roughly USD 900 million annual budget supports the basic science feeding the device pipeline.
Long-Term Outlook for Artificial Retinas in the United States
By 2032, the U.S. artificial retina market is expected to shift from a single-device, academic-trial category into a small commercial market anchored by one or two subretinal or suprachoroidal systems. Revenue of USD 112.0 million reflects roughly 500 implant procedures annually across eligible centers, with per-procedure economics improved by TCET coverage and standardized surgical protocols.
Competitive dynamics will hinge on whether a subretinal leader converts PRIMA trial outcomes into U.S. approval before 2029, and whether Retina Implant AG's Alpha AMS and Nanoretina's designs achieve comparable durability. Hospital systems will consolidate implant programs around three to five regional centers, and device-service contracts will become a recurring revenue layer for manufacturers that survive the transition.
Frequently Asked Questions
Market Segmentation
- Epiretinal
- Subretinal
- Suprachoroidal
- Optogenetic Therapy
- Academic Medical Centers
- Ophthalmic Hospitals
- Veterans Affairs Medical Centers
- Ambulatory Surgery Centers
- Retinitis Pigmentosa
- Stargardt Disease
- Choroideremia
- Geographic Atrophy
Table of Contents
Research Framework and Methodological Approach
Information
Procurement
Information
Analysis
Market Formulation
& Validation
Overview of Our Research Process
MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.
1. Data Acquisition Strategy
Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.
- Company annual reports & SEC filings
- Industry association publications
- Technical journals & white papers
- Government databases (World Bank, OECD)
- Paid commercial databases
- KOL Interviews (CEOs, Marketing Heads)
- Surveys with industry participants
- Distributor & supplier discussions
- End-user feedback loops
- Questionnaires for gap analysis
Analytical Modeling and Insight Development
After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.
2. Market Estimation Techniques
MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.
Bottom-up Approach
Aggregating granular demand data from country level to derive global figures.
Top-down Approach
Breaking down the parent industry market to identify the target serviceable market.
Supply Chain Anchored Forecasting
MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.
Supply-Side Evaluation
Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.
3. Market Engineering & Validation
Market engineering involves the triangulation of data from multiple sources to minimize errors.
Extensive gathering of raw data.
Statistical regression & trend analysis.
Cross-verification with experts.
Publication of market study.
Client-Centric Research Delivery
MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.